Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-03 EDT			5-day change	1st Jan Change
4.57 ^SEK	-1.40%		-16.91%	-18.10%

06-20	Transcript : Egetis Therapeutics AB - Special Call
06-19	Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	CI

Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency

June 03, 2024 at 01:00 am

Egetis Therapeutics AB (publ) announced that it has received a Promising Innovative Medicine (PIM) designation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the investigational drug Emcitate® (tiratricol) in the treatment of monocarboxylate transporter 8 (MCT8) deficiency.

Latest news about Egetis Therapeutics AB

Transcript : Egetis Therapeutics AB - Special Call	06-20
Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	06-19	CI
Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency	06-03	CI
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	12-22	CI
Transcript : Egetis Therapeutics AB - Analyst/Investor Day	12-19
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	12-13	CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	11-10	MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Egetis Therapeutics' Marketing Authorization Application for Emcitate Validated in EU	23-10-27	MT
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency	23-10-27	CI
Egetis Therapeutics AB Secures Combined Financing of Approximately SEK 462 Million	23-10-11	CI
Egetis Therapeutics Raises SEK462 Million Via Private Placement, Debt Financing	23-10-11	MT
Egetis Therapeutics AB announced that it expects to receive SEK 461.821824 million in funding from Frazier Life Sciences Management, LP, Cidro Förvaltning AB,	23-10-09	CI
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe	23-10-09	MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency	23-10-09	CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial	23-07-24	CI
Transcript : Egetis Therapeutics AB - Special Call	23-06-29
Egetis Therapeutics AB Announces Site Activation in the Pivotal Retriact Trial for Emcitate	23-06-28	CI
Egetis Terminates Discussions Regarding Potential Acquisition	23-05-24	CI
Egetis Therapeutics Ends Talks for Potential Takeover	23-05-24	MT
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI

Chart Egetis Therapeutics AB

Duration

Period

More charts

Company Profile

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Egetis Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.635 SEK

Average target price

13.3 SEK

Spread / Average Target

+186.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
EGETIS THERAPEUTICS AB	-18.10%	128M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs